Achievable logoAchievable logo
USMLE/1
Sign in
Sign up
Purchase
Textbook
Support
How it works
Resources
Exam catalog
Mountain with a flag at the peak
Textbook
Introduction
1. Anatomy
2. Microbiology
3. Physiology
4. Pathology
4.1 General pathology
4.2 Central and peripheral nervous system
4.3 Cardiovascular system
4.4 Respiratory system
4.5 Hematology and oncology
4.6 Gastrointestinal pathology
4.7 Renal, endocrine and reproductive system
4.7.1 Renal system
4.7.2 Diabetes mellitus
4.7.3 Diabetic symptoms
4.7.4 Metabolic syndrome or Syndrome X
4.7.5 Thyroid disorders
4.7.6 Hypothyroidism
4.7.7 Hyperthyroidism
4.7.8 Malignancies of the thyroid gland
4.7.9 Parathyroid disorders
4.7.10 Hypoparathyroidism
4.7.11 Adrenal disorders
4.7.12 Adrenal insufficiency
4.7.13 Cushing’s syndrome
4.7.14 Additional information
4.8 Musculoskeletal system
5. Pharmacology
6. Immunology
7. Biochemistry
8. Cell and molecular biology
9. Biostatistics and epidemiology
10. Genetics
11. Behavioral science
Wrapping up
Achievable logoAchievable logo
4.7.8 Malignancies of the thyroid gland
Achievable USMLE/1
4. Pathology
4.7. Renal, endocrine and reproductive system

Malignancies of the thyroid gland

2 min read
Font
Discuss
Share
Feedback

On microscopy, thyroid cancer can be papillary, follicular, medullary, or anaplastic.

Risk factors include:

  • Family history
  • Female sex
  • Previous neck irradiation

Non-Hodgkin’s lymphoma can occur in Hashimoto’s thyroiditis.

Anaplastic carcinoma has a poor prognosis.

Common presentations include:

  • Neck mass
  • Thyroid nodule
  • Lymphadenopathy
  • Dysphagia
  • Dyspnea
  • Fatigue
  • Weight loss

Evaluation typically starts with ultrasound. Ultrasound findings that suggest malignancy include:

  • Microcalcifications
  • Increased vascularity
  • Hypoechoic mass

Ultrasound is followed by biopsy.

An iodine scan may show a cold or hot nodule.

Serum thyroglobulin is a tumor marker for thyroid cancers.

Treatment is with thyroidectomy plus RAI (radioiodine ablation) and TSH suppression.

  • Lobectomy is done for small nodules without local or distant spread.
  • Total thyroidectomy is done for lesions greater than 1 cm.
  • Lymph node dissection is done in the presence of metastatic lymphadenopathy.
  • RAI helps control distant metastases.
  • TSH suppression is done by administering thyroid hormone.

Medullary carcinoma is always treated with thyroidectomy. Calcitonin can be used as a tumor marker.

Types of thyroid cancers

Type Features
Papillary RET and BRAF mutations; multiple foci; shows papillary projections, Psammoma bodies, Orphan Annie nuclei
Follicular Abnormal follicles, capsular and vascular invasion
Medullary Origin from parafollicular C cells, amyloid deposits, calcitonin positive; associated with MEN 2A and B; RET mutations
Anaplastic P53 and BRAF mutations; poorly differentiated, giant cells

Types of thyroid cancer

  • Papillary, follicular, medullary, anaplastic
  • Papillary: RET/BRAF mutations, papillary projections, Psammoma bodies, Orphan Annie nuclei
  • Follicular: abnormal follicles, capsular/vascular invasion
  • Medullary: parafollicular C cell origin, amyloid, calcitonin positive, MEN 2A/2B, RET mutations
  • Anaplastic: P53/BRAF mutations, poorly differentiated, giant cells

Risk factors

  • Family history
  • Female sex
  • Previous neck irradiation
  • Hashimoto’s thyroiditis (risk for Non-Hodgkin’s lymphoma)

Clinical presentation

  • Neck mass or thyroid nodule
  • Lymphadenopathy
  • Dysphagia, dyspnea
  • Fatigue, weight loss

Diagnosis and evaluation

  • Initial test: ultrasound
    • Malignancy signs: microcalcifications, increased vascularity, hypoechoic mass
  • Follow-up: biopsy
  • Iodine scan: cold or hot nodule
  • Serum thyroglobulin: tumor marker (except medullary)
  • Calcitonin: tumor marker for medullary carcinoma

Treatment

  • Thyroidectomy (lobectomy for small, localized nodules; total for >1 cm lesions)
  • Lymph node dissection if metastatic lymphadenopathy
  • Radioiodine ablation (RAI) for distant metastases
  • TSH suppression with thyroid hormone
  • Medullary carcinoma: always thyroidectomy
    • Associated with calcitonin as marker, MEN 2A/2B

Prognosis

  • Anaplastic carcinoma: poor prognosis

Sign up for free to take 1 quiz question on this topic

All rights reserved ©2016 - 2026 Achievable, Inc.

Malignancies of the thyroid gland

On microscopy, thyroid cancer can be papillary, follicular, medullary, or anaplastic.

Risk factors include:

  • Family history
  • Female sex
  • Previous neck irradiation

Non-Hodgkin’s lymphoma can occur in Hashimoto’s thyroiditis.

Anaplastic carcinoma has a poor prognosis.

Common presentations include:

  • Neck mass
  • Thyroid nodule
  • Lymphadenopathy
  • Dysphagia
  • Dyspnea
  • Fatigue
  • Weight loss

Evaluation typically starts with ultrasound. Ultrasound findings that suggest malignancy include:

  • Microcalcifications
  • Increased vascularity
  • Hypoechoic mass

Ultrasound is followed by biopsy.

An iodine scan may show a cold or hot nodule.

Serum thyroglobulin is a tumor marker for thyroid cancers.

Treatment is with thyroidectomy plus RAI (radioiodine ablation) and TSH suppression.

  • Lobectomy is done for small nodules without local or distant spread.
  • Total thyroidectomy is done for lesions greater than 1 cm.
  • Lymph node dissection is done in the presence of metastatic lymphadenopathy.
  • RAI helps control distant metastases.
  • TSH suppression is done by administering thyroid hormone.

Medullary carcinoma is always treated with thyroidectomy. Calcitonin can be used as a tumor marker.

Types of thyroid cancers

Type Features
Papillary RET and BRAF mutations; multiple foci; shows papillary projections, Psammoma bodies, Orphan Annie nuclei
Follicular Abnormal follicles, capsular and vascular invasion
Medullary Origin from parafollicular C cells, amyloid deposits, calcitonin positive; associated with MEN 2A and B; RET mutations
Anaplastic P53 and BRAF mutations; poorly differentiated, giant cells
Key points

Types of thyroid cancer

  • Papillary, follicular, medullary, anaplastic
  • Papillary: RET/BRAF mutations, papillary projections, Psammoma bodies, Orphan Annie nuclei
  • Follicular: abnormal follicles, capsular/vascular invasion
  • Medullary: parafollicular C cell origin, amyloid, calcitonin positive, MEN 2A/2B, RET mutations
  • Anaplastic: P53/BRAF mutations, poorly differentiated, giant cells

Risk factors

  • Family history
  • Female sex
  • Previous neck irradiation
  • Hashimoto’s thyroiditis (risk for Non-Hodgkin’s lymphoma)

Clinical presentation

  • Neck mass or thyroid nodule
  • Lymphadenopathy
  • Dysphagia, dyspnea
  • Fatigue, weight loss

Diagnosis and evaluation

  • Initial test: ultrasound
    • Malignancy signs: microcalcifications, increased vascularity, hypoechoic mass
  • Follow-up: biopsy
  • Iodine scan: cold or hot nodule
  • Serum thyroglobulin: tumor marker (except medullary)
  • Calcitonin: tumor marker for medullary carcinoma

Treatment

  • Thyroidectomy (lobectomy for small, localized nodules; total for >1 cm lesions)
  • Lymph node dissection if metastatic lymphadenopathy
  • Radioiodine ablation (RAI) for distant metastases
  • TSH suppression with thyroid hormone
  • Medullary carcinoma: always thyroidectomy
    • Associated with calcitonin as marker, MEN 2A/2B

Prognosis

  • Anaplastic carcinoma: poor prognosis